Back to Research

Organization profile

Aukera Therapeutics

Aukera Therapeutics is a preclinical-stage biotech organization that specializes in the development of first-in-class RAPTOR inhibitors for the treatment of mTORC1-related pathologies. By leveraging a proprietary AI-driven discovery platform, the company targets rare neurological disorders, cancer, and age-related diseases through selective modulation of cellular growth pathways.26

Basel, SwitzerlandFounded 2021

Overview

1. Executive Summary (Confidence: High)

Aukera Therapeutics GmbH, a 2021 spin-off from the University of Basel’s Biozentrum, is a high-impact player in the geroscience and oncology sector. The company was founded on seminal academic research from the laboratories of Professors Michael N. Hall (the discoverer of TOR) and Timm Maier. Aukera is developing the first "RAPTOR inhibitors" designed to selectively target the mTORC1 signaling network—the cell's primary growth engine—without disrupting the critical survival functions of mTORC2. This selective approach addresses the severe toxicity and efficacy limitations of previous generations of mTOR inhibitors like rapamycin. Officially emerging from stealth in late 2025, the company has raised approximately CHF 4.5 million in funding from investors including Kickfund and Zürcher Kantonalbank. Led by CEO Stefan Imseng, Aukera is currently advancing its lead program into preclinical efficacy studies for Tuberous Sclerosis Complex (TSC) and has a strategic roadmap targeting neurodegeneration and metabolic disorders.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.